Bosentan: new indication. Also too risky in mildly symptomatic pulmonary arterial hypertension. No proven tangible benefit in mildly symptomatic patients, and too many adverse effects.
D017277:Drug Approval; D005060:Europe; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D013449:Sulfonamides